Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Roche Holdings ADR RHHBY

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue... see more

OTCQX:RHHBY - Post Discussion

Roche Holdings ADR > Kadcyla Inventor
View:
Post by Goldnboy1 on Oct 05, 2021 1:46am

Kadcyla Inventor

Took on a role at $APC.v. 

$APC.v was selected for a presentation at the World Molegular Imaging Congress. 

This is a merit based selection and was awarded because of the positive results of their Zeglis Lab trials. More details of which will be explained to the WMIC tomorrow. 

Quite interesting to see a company this small invited to a world leading medical conference to present. This is not a pay to play promo conference. This is an industry staple where blue chip biotech's are more likely to be presenting than the entry level biotechs. 

I'm hearing Dr. Ravi Chari the combination of matter patent inventor for Kadcyla has taken a role with $APC because he see's an opportunity in the patent portfolio to both recessitate failed chemo/radiation drugs. But also to develop new drugs from scratch.

Not to mention this company has isolated six candidates for covid therapies. Given the variant situation who knows how many unique therapies will be needed to treat covid long term. $APC has a chance to deliver one or more of those solutions!

Have to think with programs this lit, and blue chip biotechs so cash rich. It won't be long before a company like $APC has a new shareholder, licence or a financing lead by a major biotech company. 

In times like these investments like that are like outsourcing work with a cherry if you succeed. This day doesn't feel far away!

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities